Page 184 - Haematologica May 2022

Letters to the Editor
≥70 years, platelet count ≥450 x 109/L, cytogenetic sub- types (as per CPSS stratification), SF3B1 and ASXL1 mutations, and bone marrow blast percentage ≥5, and found that SF3B1 mutations retained their independent favorable prognostic impact (P=0.01) (Online Supplementary Table S2).
In summary, our data indicate that SF3B1-mutant MDS/MPN is a clinically and genomically distinct catego- ry within overlap myeloid neoplasms and, pending fur- ther validation, should be considered as a unique prog- nostic entity. Additionally, patients with this condition have distinct clinical and molecular characteristics in comparison to SF3B1-mutant MDS patients, arguing against a uniform classification category of SF3B1- mutant myeloid neoplasms.
Limitations of our study include smaller numbers of patients in certain subgroup comparisons, differential fol- low-up times and therapy choices, and selection biases largely due to the retrospective nature of the analyses.
Abhishek A. Mangaonkar,1 Terra L. Lasho,1 Christy Finke,1 Rhett P. Ketterling,2 Kaaren K. Reichard,2 Kristen McCullough,1 Naseema Gangat,1 Aref Al-Kali,1 Kebede H. Begna,1 William H. Hogan,1 Mark R. Litzow,1 Hassan Alkhateeb,1 Mithun Shah,1 Animesh Pardanani,1 Ayalew Tefferi,1 Najla H. Al Ali,3 Chetasi Talati,3 David Sallman,3 Eric Padron,3 Rami Komrokji3 and Mrinal M. Patnaik1
1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN; 2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN and 3Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Correspondence:
MRINAL M. PATNAIK - patnaik.mrinal@mayo.edu
RAMI KOMROKJI - Rami.Komrokji@moffitt.org
doi:10.3324/haematol.2021.280463
Received: December 7, 2021.
Accepted: January 28, 2022.
Pre-published: February 10, 2022.
Disclosures: AM has received research funding from BMS. EP has received honoraria from and/or serves on advisory boards for BluePrint, CTI, Stemline Therapeutics, Taiho and BMS; and has received research funding from Kura, Incyte, and BMS. MP has received research funding from Kura Oncology and Stemline Pharmaceuticals. All other authors declare that they have no conflicts of interest.
Contributions: AM compiled the clinical and genomics data, ana- lyzed data, and wrote all the drafts of the manuscript. TL and CF per- formed the genomics analysis. RPK and KKR reviewed the pathology information and edited all drafts of the manuscript. KM, NG, AAK,
KHB, WHH, MRL, HA, MS, AP, and AT contributed patients and edited all drafts of the manuscript. NHA, CT, DS, EP and RK con- tributed data from the external (validation) cohort and edited all drafts of the manuscript. MP conceptualized the study and edited all drafts of the manuscript. All authors contributed to the writing of the manuscript.
Funding: this publication was supported by grant #UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS); however, the findings do not necessarily represent official views of the National Institutes of Health.
Data-sharing statement: for original data, please contact patnaik.mrinal@mayo.edu
References
1. Patnaik MM, Itzykson R, Lasho T, et al. ASXL1 and SETBP1 muta- tions and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206.
2. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-548.
3. Patnaik MM, Lasho TL, Finke CM, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS- T) and the role of next-generation sequencing. Am J Hematol. 2016;91(5):492-498.
4. Mangaonkar AA, Swoboda DM, Coltro G, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia. 2020;34(2):656-661.
5. Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neo- plasms. Blood. 2020;136(16):1851-1862.
6. Mangaonkar AA, Swoboda DM, Lasho TL, et al. Genomic stratifica- tion of myelodysplastic/myeloproliferative neoplasms, unclassifi- able: sorting through the unsorted. Leukemia. 2021;35(11):3329- 3333.
7. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation iden- tifies a distinct subset of myelodysplastic syndrome with ring sider- oblasts. Blood. 2015;126(2):233-241.
8.Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157- 170.
9. Wudhikarn K, Loghavi S, Mangaonkar AA, et al. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv. 2020;4(22):5716- 5721.
10. Valent P, Orazi A, Savona MR, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML vari- ants and pre-CMML conditions. Haematologica. 2019;104(10):1935- 1949.
11. Such E, Germing U, Malcovati L, Hrodek O. Development and vali- dation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Transfuze a Hematologie Dnes. 2013;19(3):191.
1192
haematologica | 2022; 107(5)